## Daily Biotech / Pharma Headlines ### Top Stories - **[Revolution's RAS inhibitor doubles pancreatic survival](https://endpoints.news/revolution-medicines-pancreatic-cancer-drug-doubles-survival-time-in-phase-3/)** — Endpoints News (5 sources) - **[Regeneron forms up to $4.3B radiopharma alliance](https://www.biospace.com/deals/regeneron-enters-radiopharma-ring-with-up-to-4-3b-telix-alliance)** — BioSpace Business (2 sources) - **[BioNTech HER2 ADC posts positive Phase 2 results](https://endpoints.news/biontechs-her2-adc-succeeds-in-phase-2-study-fda-filing-planned/)** — Endpoints News ### Regulatory & FDA - [FDA warns sponsors to report trial results](http://www.fda.gov/news-events/press-announcements/fda-reminds-more-2200-sponsors-and-researchers-disclose-trial-results) — FDA ### Clinical & Research - [IDEAYA's eye cancer drug aims for FDA filing](https://www.biospace.com/drug-development/ideaya-and-serviers-eye-cancer-drug-heads-to-fda-after-delivering-best-in-class-efficacy) — BioSpace Drug Development - [Ideaya uveal melanoma drug meets success benchmark](https://endpoints.news/ideayas-uveal-melanoma-drug-exceeds-success-benchmark-in-late-stage-trial/) — Endpoints News - [Off-the-shelf CAR-T may delay lymphoma relapse](https://www.biopharmadive.com/news/allogene-cema-cel-allogeneic-lymphoma-data/817316/) — BioPharma Dive (3 sources) - [Spyre's IBD drug shows early promise](https://www.biopharmadive.com/news/spyre-inflammatory-bowel-disease-drug-results-a4b7/817298/) — BioPharma Dive (2 sources) - [Allogene's off-the-shelf CAR-T shows strong early responses](https://endpoints.news/allogenes-first-cut-of-data-on-off-the-shelf-car-t-shows-promise/) — Endpoints News ### Deals & Finance - [AbbVie licenses pain candidate from Haisco](https://www.biospace.com/business/abbvie-enters-world-of-pain-in-up-to-715m-deal-with-chinas-haisco) — BioSpace Business - [Seaport and Hemab file to go public](https://www.biospace.com/business/ipo-tracker-2026) — BioSpace Business - [Updated IPO filings: Seaport, Hemab, Kailera](https://endpoints.news/seaport-and-hemab-file-for-ipos-with-kailera-expected-to-price-soon/) — Endpoints News ### Company News - [Replimune faces second regulatory rejection](https://www.biospace.com/business/second-rejection-for-tumor-destroyer-puts-replimune-on-a-challenging-path) — BioSpace Business ### Policy & Politics - [MHRA, eBay remove dangerous medicine listings](https://www.gov.uk/government/news/mhra-and-ebay-working-in-partnership-to-safeguard-public-health) — MHRA ### Market Insights - [USP flags drugs vulnerable to supply disruptions](https://www.biospace.com/business/usp-adds-tamiflu-trulicity-to-vulnerable-list-as-upstream-analysis-reshapes-supply-concerns) — BioSpace Business
Daily Biotech / Pharma Headlines
Top Stories
Regulatory & FDA
Clinical & Research
Deals & Finance
Company News
Policy & Politics
Market Insights